Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 2—February 2020
Research

Chronic Human Pegivirus 2 without Hepatitis C Virus Co-infection

Kelly E. CollerComments to Author , Veronica Bruce, Michael Cassidy, Jeffrey Gersch, Matthew B. Frankel, Ana Vallari, Gavin Cloherty, John Hackett, Jennifer L. Evans, Kimberly Page, and George J. Dawson
Author affiliations: Abbott Laboratories, Abbott Park, Illinois, USA (K.E. Coller, M. Cassidy, J. Gersch, M.B. Frankel, A. Vallari, G. Cloherty, J. Hackett, Jr., G.J. Dawson); University of New Mexico, Albuquerque, New Mexico, USA (V. Bruce, K. Page); University of California San Francisco, San Francisco, California, USA (J.L. Evans)

Main Article

Table 4

Information about participants with HPgV-2 infection without HCV co-infection in study of injection drug users in the San Francisco Bay area, California, USA*

Sample ID Age, y/sex No. years drug use† Collection date NS2/3 log10 copies/mL 5′ UTR log10 copies/mL NS4AB S/CO‡ E2 S/CO‡
QM0003 28.4/F 14.4 2015 Oct 10 3.76 2.84 0.12 0.08
2015 Nov 4 0.93 0.55 0.08 0.08
2016 Jan 27 2.66 1.10 0.16 0.72
2016 Apr 18 3.56 1.62 0.07 0.85
2016 Jul 13 3.66 1.61 § §
2016 Oct 5 3.22 1.74 0.13 2.76
2017 Jan 4 4.22 2.30 0.25 4.67
2017 Apr 10 3.85 2.10 0.17 3.58
2017 Jul 5 4.08 2.39 0.28 3.73
2018 Feb 7
 3.41
 1.34
 0.37
 2.66
VP0295 24.6/M 3.1 2016 Jan 6 Neg Neg 0.10 0.12
2016 Apr 6 Neg Neg 0.09 0.11
2016 Aug 24 Neg Neg 0.12 0.11
2017 Jan 4 4.44 2.82 0.11 0.14
2017 Apr 12 3.19 1.06 0.09 0.89
2017 Jul 12
 1.42
 0.82
 0.15
 5.51
GG0012 23.4/F 3.4 2016 Apr 29 Neg Neg 0.23 0.52
2016 Aug 17 Neg Neg 1.77 3.28
2016 Nov 29 Neg Neg 3.18 5.76
2017 Mar 1 Neg Neg 4.90 8.90
2017 May 31 Neg Neg 2.60 4.51
2017 Sep 20 Neg Neg 4.05 10.94
2017 Dec 13 Neg Neg 6.03 11.04
2018 Mar 19
 Neg
 Neg
 3.77
 6.67
VH0052 23.7/M 3.5 2006 Dec 14 2.13 1.23 2.00 1.91
2007 Jul 3
 Neg
 Neg
 0.81
 1.63
RM0095 27.1/M 1.1 2011 Jan 19 Neg Neg 0.06 0.06
2011 Jul 27 0.02 0.14 0.07 0.09
2011 Oct 19 2.33 1.54 0.06 0.29
2012 Jan 11 0.20 0.50 0.09 0.59
2012 Apr 11 0.02 0.16 0.24 0.50
2012 Jul 3 Neg Neg 0.14 0.59
2012 Oct 23 0.03 0.27 0.12 1.09
2013 Jan 15 0.45 0.61 0.15 2.45
2013 Apr 10 1.37 1.08 0.13 2.37
2013 Jul 2 Neg Neg 0.17 3.53
2013 Sep 18 0.46 0.55 0.14 2.64
2013 Dec 11 Neg Neg 0.14 3.07

*Participants were determined negative for HCV by RNA or antibody test. HCV, hepatitis C virus; HPgV-2, human pegivirus 2; ID, identification; neg, negative; NS, nonstructural protein; pos, positive; S/CO, signal to cutoff value; UTR, untranslated region.
†Number of years participant had injected drugs as of the time of the initial blood draw.
‡S/CO >1.0 is considered positive.
§No blood sample available for testing.

Main Article

Page created: January 17, 2020
Page updated: January 17, 2020
Page reviewed: January 17, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external